From: Smoking is associated with pneumonia development in lung cancer patients
Characteristic | Pneumonia (n = 118) | Non-pneumonia (n = 295) | p-value |
---|---|---|---|
Age, year | 69.79 ± 8.35 | 66.37 ± 10.60 | 0.002 |
Sex, male | 98 (83.1) | 205 (69.5) | 0.005 |
BMI, kg/m2 | 22.80 ± 2.943 | 23.52 ± 3.121 | 0.887 |
Smoking history | Â | Â | 0.002 |
 Never | 17 (14.4) | 91 (30.8) | 0.001 |
 Former | 53 (44.9) | 113 (38.3) | 0.216 |
 Current | 48 (40.7) | 91 (30.8) | 0.056 |
 Pack-years | 39.85 ± 23.83 | 39.89 ± 25.50 | 0.992 |
 Underlying disease | 97 (82.2) | 235 (78.9) | 0.444 |
 Accompanied cancer | 15 (12.7) | 47 (75.8) | 0.430 |
Pathology | Â | Â | 0.004 |
 Adenocarcinoma | 53 (44.9) | 183 (62.0) | 0.002 |
 SqCC | 32 (27.1) | 64 (21.7) | 0.238 |
 SCLC | 29 (24.6) | 29 (9.8) | < 0.001 |
 Adenosquamous | 1 (0.8) | 5 (1.7) | 0.516 |
 Large cell | 1 (0.8) | 2 (0.7) | 0.885 |
 NOS | 0 (0) | 1 (0.3) | 0.527 |
 Mesothelioma | 0 (0) | 0 (0) |  |
 Others | 2 (1.7) | 8 (2.7) | 0.354 |
Line of therapy | Â | Â | 0.067 |
 0 | 7 (5.9) | 24 (8.2) |  |
 1 | 57 (48.3) | 139 (47.3) |  |
 2 | 25 (21.2) | 87 (29.6) |  |
  ≥ 3 | 29 (24.6) | 44 (15.0) |  |
Neutropenia | 51 (43.2) | 56 (18.9) | < 0.001 |
PFT | |||
 FVC, % pred | 82.25 ± 16.810 | 87.77 ± 19.349 | 0.218 |
 FEV1, % pred | 78.39 ± 19.219 | 83.93 ± 22.878 | 0.083 |
 FEV1/FVC < 70% | 47 (49.5) | 93 (40.8) | 0.151 |
 FEV1/FVC | 0.90 ± 0.297 | 0.93 ± 0.259 | 0.103 |
Clinical stage |  |  | < 0.001 |
 I | 15 (12.7) | 100 (33.9) | < 0.001 |
 II | 10 (8.5) | 19 (4.6) | 0.476 |
 III | 47 (39.8) | 50 (16.9) | < 0.001 |
 IV | 46 (39.0) | 124 (42.0) | 0.534 |
Treatment modality |  |  | < 0.001 |
 No therapy | 7 (5.9) | 22 (7.5) | 0.567 |
 Surgery | 26 (22.0) | 107 (36.6) | 0.004 |
 Chemotherapy | 47 (39.8) | 75 (25.7) | 0.005 |
 TKI | 7 (5.9) | 47 (16.1) | 0.006 |
 CCRT | 17 (14.4) | 18 (6.2) | 0.007 |
 SBRT | 0 (0) | 2 (0.7) | 0.367 |
 RT | 11 (9.3) | 14 (4.8) | 0.083 |
 Neo-adjuvant CCRT | 0 (0) | 3 (1.0) | 0.247 |